Prescription drugs
SAN FRANCISCO — The Ninth Circuit upheld a ruling against a woman who claimed Otsuka America Pharmaceutical’s antipsychotic drug Abilify caused her to develop tardive dyskinesia. The court ruled the woman did not prove the company failed to warn of a known or scientifically knowable risk at the time the drug was distributed.
Read the opinion here.
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing
trials, major litigation and rulings in courthouses around the U.S. and the world, while the
monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech
and the arts.